“Characterizing Deep Quality-of-Life Response in the TRuE-V1/TRuE-V2 Studies of Ruxolitinib Cream in Nonsegmental Vitiligo” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s752. doi:10.25251/bpnxm492.